Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

The Dystrophic Epidermolysis Bullosa Market has been comprehensively analyzed in IMARC's new report titled "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Dystrophic epidermolysis bullosa refers to a rare genetic condition that causes the skin to blister or tear easily. The response could be to a minor injury or friction, such as rubbing or scratching or even from heat. The signs and symptoms of dystrophic epidermolysis bullosa generally differ among individuals. In mild cases, blistering may affect hands, feet, knees, and elbows, while in severe cases, widespread blistering occurs, which leads to scarring, vision loss, and other medical problems. The disease is diagnosed by identifying biallelic pathogenic variants (RDEB) or a heterozygous pathogenic variant (DDEB) in COL7A1 by molecular genetic testing. Currently, the available treatment focuses on managing symptoms and complications. Some of the common treatment available for dystrophic epidermolysis bullosa, include moisturizers to lessen friction and irritation, non-adhesive bandages and dressings to protect the wound, and medicines to ease the pain.

The rising incidences of rare genetic disorders coupled with the inflating demand for novel medications that can treat the conditions effectively are primarily driving the global dystrophic epidermolysis bullosa market. Besides this, the increasing patient willingness to pay for expensive treatments, such as gene therapy, cell-based therapy, molecular therapy, etc., is further augmenting the global market. Moreover, the emerging popularity of non-adhesive semiocclusive dressings, including soft  silicone and foam dressings, for treating dystrophic epidermolysis bullosa since they absorb exudate and reduce pain and blister formation during dressing is also acting as another growth-inducing factor. In addition to this, numerous stakeholders are making significant investments in R&D activities to gain a clear understanding of the disease etiopathogenesis for developing new and cutting-edge therapy alternatives. This, in turn, is further creating a positive outlook for the market. Furthermore, the introduction of several treatment alternatives, such as stem cell transplantation and gene correction, is also bolstering the market growth. Additionally, the escalating need for more effective and personalized therapies with improved long-term side effect profiles is further expected to bolster the global dystrophic epidermolysis bullosa market in the coming years.

IMARC Group's new report "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Dystrophic Epidermolysis Bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Dystrophic Epidermolysis Bullosa market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Dystrophic Epidermolysis Bullosa across the seven major markets. According to the report the United States has the largest patient pool for Dystrophic Epidermolysis Bullosa and also represents the largest market for Dystrophic Epidermolysis Bullosa treatment. Furthermore, the current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dystrophic Epidermolysis Bullosa market in any manner.

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Dystrophic Epidermolysis Bullosa Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Dystrophic Epidermolysis Bullosa Market
  • Sales of Various Drugs Across the Dystrophic Epidermolysis Bullosa Market
  • Reimbursement Scenario in the Dystrophic Epidermolysis Bullosa Market
  • In-Market and Pipeline Drugs
     

This report also provides a detailed analysis of the current Dystrophic Epidermolysis Bullosa marketed drugs and late-stage pipeline drugs.
 

In-Market Dystrophic Epidermolysis Bullosa Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Dystrophic Epidermolysis Bullosa Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status
     

Key Questions Answered in this Report

Market Insights

  • How has the Dystrophic Epidermolysis Bullosa market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Dystrophic Epidermolysis Bullosa market across the seven major markets in 2021 and how will it look like in 2032?
  • What is the growth rate of the Dystrophic Epidermolysis Bullosa market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Dystrophic Epidermolysis Bullosa market?
     

Epidemiology Insights

  • What is the size of the Dystrophic Epidermolysis Bullosa patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Dystrophic Epidermolysis Bullosa across the seven major markets?
  • What are the key factors driving the epidemiological trend of Dystrophic Epidermolysis Bullosa?
  • What will be the growth rate of Dystrophic Epidermolysis Bullosa patients across the seven major markets?
     

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their market performance?
  • What are the key pipeline Dystrophic Epidermolysis Bullosa drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?
  • How safe are the late-stage pipeline Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?
  • What are the current treatment guidelines for Dystrophic Epidermolysis Bullosa drugs across the seven major markets?
  • Who are the key companies in the Dystrophic Epidermolysis Bullosa market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Dystrophic Epidermolysis Bullosa market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Dystrophic Epidermolysis Bullosa - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Dystrophic Epidermolysis Bullosa - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Dystrophic Epidermolysis Bullosa - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Dystrophic Epidermolysis Bullosa - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Dystrophic Epidermolysis Bullosa Guidelines, Management and Treatment
8.2 Dystrophic Epidermolysis Bullosa Treatment Algorithm

9 Dystrophic Epidermolysis Bullosa - Unmet Needs

10 Dystrophic Epidermolysis Bullosa - Key Endpoints of Treatment

11 Dystrophic Epidermolysis Bullosa - Marketed Products
11.1 List of Dystrophic Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets
11.1.1    Filsuvez (Birch triterpenes) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

12 Dystrophic Epidermolysis Bullosa - Pipeline Drugs
12.1 List of Dystrophic Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
12.1.1 Dabocemagene autoficel - Fibrocell Science
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Beremagene geperpavec - Krystal Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 EB-101 - Abeona Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PTR-01 - Phoenix Tissue Repair
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Timbetasin - RegeneRx Biopharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13. Dystrophic Epidermolysis Bullosa - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Dystrophic Epidermolysis Bullosa - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Dystrophic Epidermolysis Bullosa - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Dystrophic Epidermolysis Bullosa - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Dystrophic Epidermolysis Bullosa - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Dystrophic Epidermolysis Bullosa - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Dystrophic Epidermolysis Bullosa - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Dystrophic Epidermolysis Bullosa - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Dystrophic Epidermolysis Bullosa - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Dystrophic Epidermolysis Bullosa  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview

15 Dystrophic Epidermolysis Bullosa - Recent Events and Inputs From Key Opinion Leaders

16 Dystrophic Epidermolysis Bullosa Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4